RESEARCH ARTICLE PharmacodynamicImpact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors Karl Emil Nelveg-Kristensen1*, Peter Bie2, Laura Ferrero3, Ditte Bjerre3, Niels E. Bruun1,5, Martin Egfjord4, Henrik B. Rasmussen3³, Peter R. Hansen1, INDICES Consortium¶ 1 Department of Cardiology, Gentofte University Hospital, Gentofte, Denmark, 2 Institute of Molecular a11111 Medicine, University of Southern Denmark, Odense, Denmark, 3 Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, Copenhagen University Hospital, Roskilde, Denmark, 4 Department of Nephrology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 5 Clinical Institute, Aalborg University, Aalborg, Denmark ³ Lead author of the INDICES Consortium ¶ Membership of the INDICES Consortium is provided in the Acknowledgments. *
[email protected] OPEN ACCESS Citation: Nelveg-Kristensen KE, Bie P, Ferrero L, Bjerre D, Bruun NE, Egfjord M, et al. (2016) Abstract Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors. PLoS ONE 11(9): e0163341. Background doi:10.1371/journal.pone.0163341 Variation in the carboxylesterase 1 gene (CES1) may contribute to the efficacy of ACEIs. Editor: Katriina Aalto-Setala, University of Tampere, Accordingly, we examined the impact of CES1 variants on plasma angiotensin II (ATII)/ FINLAND angiotensin I (ATI) ratio in patients with congestive heart failure (CHF) that underwent Received: February 3, 2016 ACEI dose titrations. Five of these variants have previously been associated with drug response or increased CES1 expression, i.e., CES1 copy number variation, the variant of Accepted: September 7, 2016 the duplicated CES1 gene with high transcriptional activity, rs71647871, rs2244613, and Published: September 23, 2016 rs3815583.